

**Abemaciclib**

## Section

Targeted therapies

## Indications

Therapeutic equivalent to palbociclib pour

Other specified malignant neoplasms of breast

**Abiraterone**

## Section

Hormones and antihormones

Oral &gt; Solid: 250 mg; 500 mg

## Indications

Malignant neoplasms of prostate

**Afatinib**

## Section

Targeted therapies

## Indications

Therapeutic equivalent to erlotinib pour

Other specified malignant neoplasms of bronchus or lung

**All-trans retinoic acid**

## Section

Targeted therapies

Oral &gt; Solid: 10 mg capsule

## Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

**Allopurinol**

## Section

Supportive medicines

Parenteral &gt; General injections &gt; IV: 500 mg (as sodium) powder for injection

Oral &gt; Solid: 100 mg; 300 mg

## Indications

Tumour lysis syndrome

**Anastrozole**

## Section

Hormones and antihormones

Oral &gt; Solid: 1 mg tablet

## Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

## Arsenic trioxide

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

### Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

## Asparaginase

### Section

#### Cytotoxic medicines

Powder for injection: 10 000 IU in vial.

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

## Atezolizumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab pour

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab pour

Adenocarcinoma of stomach

Hepatocellular carcinoma of liver

## Axicabtagene ciloleucel

### Section

#### Antineoplastics and supportive medicines

Cell suspension for infusion:  $2 \times 10^6$  anti-CD19 CAR-positive viable T-cells per kg of body weight.

### Indications

Diffuse large B-cell lymphomas

## Axitinib

### Section

#### Targeted therapies

Oral > Solid > tablet: 1 mg; 3 mg; 5 mg

### Indications

Renal cell carcinoma of kidney, except renal pelvis

## Azacitidine

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

### Indications

Myeloid leukaemia

## Bendamustine

### Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

### Indications

Follicular lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Bevacizumab

### Section

Immunomodulators

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

### Indications

Hepatocellular carcinoma of liver

## Bicalutamide

### Section

Hormones and antihormones

Oral > Solid: 50 mg

### Indications

Malignant neoplasms of prostate

## Binimetinib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to trametinib pour

Other specified melanoma of skin

## Bleomycin

### Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)

### Indications

Germ cell tumour of testis

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of ill-defined or unspecified sites

## Blinatumomab

### Section

Immunomodulators

Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial

### Indications

B lymphoblastic leukaemia or lymphoma, not elsewhere classified

## Bortezomib

### Section

Targeted therapies

Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

### Indications

Plasma cell myeloma

## Calcium folinate (leucovorin calcium)

### Section

Cytotoxic medicines

Oral > Solid: 15 mg tablet

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant trophoblastic neoplasms of placenta

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasms of colon

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasm metastasis in large intestine

## Capecitabine

### Section

Cytotoxic medicines

Oral > Solid > tablet: 150 mg; 500 mg

### Indications

Other specified malignant neoplasms of breast

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

Malignant neoplasms of colon

## Carboplatin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

### Indications

Other specified gliomas of brain

Other specified carcinomas of ovary

Retinoblastoma

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Malignant neoplasms of kidney, except renal pelvis

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx

Malignant neoplasms of hypopharynx

Malignant neoplasms of nasopharynx

Malignant neoplasms of oropharynx

Malignant neoplasms of cervix uteri

## Cemiplimab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

### Indications

Therapeutic equivalent to pembrolizumab pour

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab pour

Adenocarcinoma of stomach

Other specified malignant neoplasms of bronchus or lung

## Chlorambucil

### Section

#### Cytotoxic medicines

Oral > Solid: 2 mg tablet

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Cisplatin

### Section

#### Cytotoxic medicines

Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection

Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Germ cell tumour of testis

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx

Malignant neoplasms of hypopharynx

Malignant neoplasms of nasopharynx

Malignant neoplasms of oropharynx

Malignant neoplasms of cervix uteri

## Cladribine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

### Indications

Langerhans cell histiocytosis

## Cobimetinib

### Section

#### Targeted therapies

### Indications

Therapeutic equivalent to trametinib pour

Other specified melanoma of skin

## Crizotinib

### Section

#### Targeted therapies

Oral > Solid: 200 mg; 250 mg

Oral > Solid > capsule: 200 mg; 250 mg

### Indications

Other specified malignant neoplasms of bronchus or lung

Anaplastic large cell lymphoma, ALK-positive

## Cyclophosphamide

### Section

#### Cytotoxic medicines

Oral > Solid: 25 mg tablet

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Oral > Solid > dosage form: 25 mg; 50 mg

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of breast

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Malignant neoplasms of breast

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Plasma cell myeloma

Other specified gliomas of brain

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Diffuse large B-cell lymphoma, not otherwise specified

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Cytarabine

### Section

#### Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

Burkitt lymphoma including Burkitt leukaemia

## Dabrafenib

### Section

Targeted therapies

Oral > Solid: 50 mg; 75 mg

### Indications

Other specified melanoma of skin

## Dacarbazine

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

### Indications

Hodgkin lymphoma

## Dactinomycin

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 µg in vial powder for injection

### Indications

Malignant trophoblastic neoplasms of placenta

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

## Daratumumab

### Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

### Indications

Plasma cell myeloma

## Darbepoetin alfa

### Section

Supportive medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Drug-induced aplastic anaemia

## Dasatinib

### Section

Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

### Indications

Chronic myeloid leukaemia, not elsewhere classified

## Daunorubicin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

### Indications

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

## Dexamethasone

### Section

#### Hormones and antihormones

Oral > Liquid: 2 mg per 5 mL

Oral > Solid: 2 mg; 4 mg

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphosphate salt)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 4 mg (as dexamethasone base)

Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)

### Indications

Anaplastic large cell lymphoma, ALK-negative

Plasma cell myeloma

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Anaplastic large cell lymphoma, ALK-positive

## Docetaxel

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

### Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Malignant neoplasms of prostate

Unspecified malignant neoplasms of ill-defined or unspecified sites

## Dostarlimab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion

### Indications

Other specified malignant neoplasms of corpus uteri

## Doxorubicin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Rhabdomyosarcoma primary site

Malignant neoplasms of breast

Hodgkin lymphoma

Plasma cell myeloma

Follicular lymphoma

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Other specified malignant neoplasms of breast

Anaplastic large cell lymphoma, ALK-positive

Ewing sarcoma of bone and articular cartilage of unspecified sites

Kaposi sarcoma of unspecified primary site

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Diffuse large B-cell lymphoma, not otherwise specified

## Doxorubicin (as pegylated liposomal)

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

### Indications

Kaposi sarcoma of unspecified primary site

## Durvalumab

### Section

Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Hepatocellular carcinoma of liver

Malignant neoplasms of biliary tract, distal bile duct

Malignant neoplasm of intrahepatic bile ducts

Malignant neoplasms of gallbladder

Malignant neoplasms of proximal biliary tract, cystic duct

## Encorafenib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to dabrafenib pour

Other specified melanoma of skin

## Enzalutamide

### Section

Hormones and antihormones

Oral > Solid: 40 mg

### Indications

Therapeutic equivalent to abiraterone pour

Malignant neoplasms of prostate

Malignant neoplasms of prostate

## Epoetin alfa

### Section

Supportive medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Drug-induced aplastic anaemia

## Epoetin beta

### Section

Supportive medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents pour

Drug-induced aplastic anaemia

## Erlotinib

### Section

#### Targeted therapies

Oral > Solid: 100 mg; 150 mg

### Indications

Other specified malignant neoplasms of bronchus or lung

## Erythropoiesis-stimulating agents

### Section

#### Supportive medicines

Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

### Indications

Drug-induced aplastic anaemia

## Etoposide

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule

Oral > Solid: 100 mg capsule

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)

Oral > Solid: 100 mg capsule; 50 mg capsule

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Ewing sarcoma of bone and articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Germ cell tumour of testis

Malignant trophoblastic neoplasms of placenta

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Hodgkin lymphoma

Retinoblastoma

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Burkitt lymphoma including Burkitt leukaemia

## Everolimus

### Section

#### Targeted therapies

Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg

Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg

### Indications

Other specified gliomas of brain

## Filgrastim

### Section

#### Immunomodulators

Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

### Indications

Acquired neutropaenia

## Fludarabine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection

Oral > Solid: 10 mg tablet (fludarabine phosphate)

### Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Fluorouracil

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule

Parenteral > General injections > IV: 50 mg per mL in vial

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of nasopharynx

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of breast

Malignant neoplasms of rectum

Malignant neoplasms of colon

## Flutamide

### Section

#### Hormones and antihormones

### Indications

Therapeutic equivalent to bicalutamide pour

Malignant neoplasms of prostate

## Fulvestrant

### Section

Hormones and antihormones

Parenteral > General injections > IV: 250 mg per 5 mL

### Indications

Malignant neoplasms of breast

## Gefitinib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to erlotinib pour

Other specified malignant neoplasms of bronchus or lung

## Gemcitabine

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

### Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

## Goserelin

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to leuprorelin pour

Malignant neoplasms of breast

Therapeutic equivalent to leuprorelin pour

Malignant neoplasms of prostate

## Hydrocortisone

### Section

Hormones and antihormones

Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

## Hydroxycarbamide (hydroxyurea)

### Section

Cytotoxic medicines

Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

### Indications

Squamous cell carcinoma of oropharynx

Chronic myeloid leukaemia, not elsewhere classified

## Ibrutinib

### Section

Targeted therapies

Oral > Solid: 140 mg

### Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Ifosfamide

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

### Indications

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Burkitt lymphoma including Burkitt leukaemia

## Imatinib

### Section

Targeted therapies

Oral > Solid: 100 mg; 400 mg

### Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, not elsewhere classified

## Ipilimumab

### Section

Immunomodulators

Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Melanoma of skin

## Irinotecan

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

### Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

## Lenalidomide

### Section

Immunomodulators

Oral > Solid: 25 mg

### Indications

Plasma cell myeloma

## Lenvatinib

### Section

Targeted therapies

Oral > Solid > capsule: 4 mg; 10 mg

### Indications

Renal cell carcinoma of kidney, except renal pelvis

## Leuprorelin

### Section

Hormones and antihormones

Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

### Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

## Lisocabtagene maraleucel

### Section

Antineoplastics and supportive medicines

### Indications

Therapeutic equivalent to axicabtagene ciloleucel pour

Diffuse large B-cell lymphomas

## Melphalan

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection

Oral > Solid: 2 mg

### Indications

Plasma cell myeloma

## Mercaptopurine

### Section

#### Cytotoxic medicines

Oral > Solid: 50 mg tablet

Oral > Liquid: 20 mg per mL

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

## Mesna

### Section

#### Supportive medicines

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule

Oral > Solid: 400 mg; 600 mg

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule

Oral > Solid > tablet: 400 mg; 600 mg

Oral > Other: 600 mg

Oral > Solid > tablet: 400 mg

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of the ovary

Osteosarcoma of bone and articular cartilage of other specified sites

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Germ cell tumour of testis

## Methotrexate

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

Oral > Solid: 2.5 mg (as sodium salt)

Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant trophoblastic neoplasms of placenta

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

## Methylprednisolone

### Section

#### Hormones and antihormones

Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)

Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection

### Indications

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

## Nilotinib

### Section

#### Targeted therapies

Oral > Solid > capsule: 150 mg; 200 mg

### Indications

Chronic myeloid leukaemia, not elsewhere classified

## Nilutamide

### Section

#### Hormones and antihormones

### Indications

Therapeutic equivalent to bicalutamide pour

Malignant neoplasms of prostate

## Nivolumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion

Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

### Indications

Therapeutic equivalent to pembrolizumab pour

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Adenocarcinoma of oesophagogastric junction

Adenocarcinoma of stomach

## Osimertinib

### Section

#### Targeted therapies

Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

### Indications

Other specified malignant neoplasms of bronchus or lung

## Oxaliplatin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

### Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

## Paclitaxel

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 6 mg per mL

### Indications

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Kaposi sarcoma of unspecified primary site

Other specified malignant neoplasms of breast

Other specified carcinomas of ovary

Malignant neoplasms of breast

Malignant neoplasms of cervix uteri

## Palbociclib

### Section

#### Targeted therapies

Oral > Solid: 75 mg; 100 mg; 125 mg

### Indications

Other specified malignant neoplasms of breast

## Panitumumab

### Section

#### Targeted therapies

Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial

### Indications

Other specified malignant neoplasms of large intestine

## Pegaspargase

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

### Indications

Lymphoid leukaemia, not elsewhere classified

## Pegfilgrastim

### Section

#### Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

### Indications

Acquired neutropaenia

## Pembrolizumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion

### Indications

Melanoma of skin

Malignant neoplasms of cervix uteri

Other specified malignant neoplasms of large intestine

Other specified malignant neoplasms of bronchus or lung

Adenocarcinoma of stomach

Squamous cell carcinoma of hypopharynx and variants

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx

Squamous cell carcinoma of oropharynx

Carcinoma of breast, specialised type

Squamous cell carcinoma of nasopharynx

Squamous cell carcinoma of oesophagus

Malignant neoplasms of oesophagogastric junction

Therapeutic equivalent to nivolumab pour

Melanoma of skin

## Pertuzumab

### Section

#### Targeted therapies

Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

### Indications

Carcinoma of breast, specialised type

## Prednisolone

### Section

Hormones and antihormones

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Plasma cell myeloma

Follicular lymphoma

Malignant neoplasms of prostate

Hodgkin lymphoma

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphoma, not otherwise specified

## Prednisone

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to prednisolone pour

Plasma cell myeloma

Therapeutic equivalent to prednisolone pour

Follicular lymphoma

Therapeutic equivalent to prednisolone pour

Malignant neoplasms of prostate

Therapeutic equivalent to prednisolone pour

Hodgkin lymphoma

Therapeutic equivalent to prednisolone pour

Anaplastic large cell lymphoma, ALK-negative

Therapeutic equivalent to prednisolone pour

Anaplastic large cell lymphoma, ALK-positive

Therapeutic equivalent to prednisolone pour

Langerhans cell histiocytosis

Therapeutic equivalent to prednisolone pour

Lymphoid leukaemia, not elsewhere classified

Therapeutic equivalent to prednisolone pour

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to prednisolone pour

Diffuse large B-cell lymphoma, not otherwise specified

## Procarbazine

### Section

Cytotoxic medicines

Oral > Solid: 50 mg (as hydrochloride)

Oral > Solid > capsule: 50 mg (as hydrochloride)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

## Rasburicase

### Section

Supportive medicines

Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution

### Indications

Tumour lysis syndrome

## Realgar-indigo naturalis formulation

### Section

Cytotoxic medicines

Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

### Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

## Ribociclib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to [palbociclib](#) pour

Other specified malignant neoplasms of breast

## Rituximab

### Section

Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

### Indications

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphoma, not otherwise specified

## Tamoxifen

### Section

Hormones and antihormones

Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

### Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

## Temozolomide

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg

### Indications

Ewing sarcoma of bone and articular cartilage of unspecified sites

Other specified gliomas of brain

Unspecified malignant neoplasms of ill-defined or unspecified sites

Neuroblastoma, NOS

## Thalidomide

### Section

Immunomodulators

Oral > Solid: 50 mg

### Indications

Plasma cell myeloma

## Tioguanine

### Section

Cytotoxic medicines

Oral > Solid: 40 mg

### Indications

Lymphoid leukaemia, not elsewhere classified

## Tisagenlecleucel

### Section

Antineoplastics and supportive medicines

### Indications

Therapeutic equivalent to axicabtagene ciloleucel pour

Diffuse large B-cell lymphomas

## Tislelizumab

### Section

Immunomodulators

Parenteral > General injections > IV: 100 mg per 10 mL

Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

### Indications

Malignant neoplasms of urinary tract

Hodgkin lymphoma

Other specified malignant neoplasms of bronchus or lung

Squamous cell carcinoma of oesophagus

## Toripalimab

### Section

Immunomodulators

Parenteral > General injections > IV: 240 mg per 6 mL in vial

### Indications

Malignant neoplasms of nasopharynx

Squamous cell carcinoma of oesophagus

## Trametinib

### Section

Targeted therapies

Oral > Solid: 0.5 mg; 2 mg

### Indications

Other specified melanoma of skin

## Trastuzumab

### Section

#### Targeted therapies

Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

### Indications

Carcinoma of breast, specialised type

## Trastuzumab emtansine

### Section

#### Targeted therapies

Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

### Indications

Carcinoma of breast, specialised type

## Tremelimumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

### Indications

Hepatocellular carcinoma of liver

Other specified malignant neoplasms of bronchus or lung

## Triptorelin

### Section

#### Hormones and antihormones

### Indications

Therapeutic equivalent to leuprorelin pour

Malignant neoplasms of breast

Therapeutic equivalent to leuprorelin pour

Malignant neoplasms of prostate

## Vemurafenib

### Section

#### Targeted therapies

### Indications

Therapeutic equivalent to dabrafenib pour

Other specified melanoma of skin

## Vinblastine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

Langerhans cell histiocytosis

## Vincristine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Kaposi sarcoma of unspecified primary site

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Retinoblastoma

Malignant neoplasms of kidney, except renal pelvis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Diffuse large B-cell lymphoma, not otherwise specified

## Vinorelbine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial

Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial

Oral > Solid > capsule: 20 mg; 30 mg; 80 mg

### Indications

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of breast

Rhabdomyosarcoma primary site

## Zanubrutinib

### Section

#### Targeted therapies

Oral > Solid: 80 mg

Oral > Solid > capsule: 80 mg

### Indications

Mantle cell lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to ibrutinib pour

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Zoledronic acid

### Section

#### Supportive medicines

Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

### Indications

Malignant neoplasm metastasis in bone or bone marrow